All In Biotech

Drug Trial Radar · NCT04652076

GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab

A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

238

Actual

Start

Dec 14, 2020

Primary completion

Oct 30, 2025

Study completion Nov 16, 2026

Sponsor

Lead sponsor
NETRIS PharmaIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; Centre Leon Berard
First posted
Dec 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial carcinoma and cervix carcinoma).

Conditions

  • Endometrial Carcinoma
  • Cervix Carcinoma

Interventions

  • NP137Drug

    Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.

  • PembrolizumabDrug

    Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.

  • PaclitaxelDrug

    Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.

  • CarboplatinDrug

    Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT occurrenceTime frame: Safety run in Period: At the end of Cycle 2 (each cycle is 21 days) for the first 6 to 12 patients per arm
  2. Overall response Rate (ORR)Time frame: At 3 months of treatement and then every 12 weeks, up to 2 years

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • CHRU BESANCON - Hopital Jean Minjoz

    Besançon, France

  • Institut Bergonié

    Bordeaux, France

  • Centre François Baclesse

    Caen, France

  • Centre Georges François Leclerc

    Dijon, France

  • Primary Completion Date

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • Primary Completion Date

    Marseille, France

  • ICM - Val d'Aurelle

    Montpellier, France

  • Insitut de cancérologie de l'ouest

    Nantes, France

  • Hopital de la Croix Saint Simon

    Paris, France

  • Institut Curie (Site Saint Cloud)

    Paris, France

  • Institut Gustave Roussy

    Paris, France

  • Aphp Cochin

    Paris, France

  • Centre Eugène Marquis

    Rennes, France

  • Institut claudius Regaud

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.